For research use only. Not for therapeutic Use.
JHU395 is an orally-bioavailable and a plasma stable lipophilic glutamine antagonists (GA) proagent. JHU395 delivers 6-diazo-5-oxo-L-norleucine (DON) to malignant peripheral nerve sheath tumor (MPNST) in vitro and in vivo, and has antitumor activity in MPNST[1].
| Catalog Number | I017823 |
| CAS Number | 2079938-92-2 |
| Synonyms | propan-2-yl (2S)-6-diazo-2-[[2,2-dimethylpropanoyloxy(phenyl)methoxy]carbonylamino]-5-oxohexanoate |
| Molecular Formula | C22H29N3O7 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H29N3O7/c1-14(2)30-18(27)17(12-11-16(26)13-24-23)25-21(29)32-19(15-9-7-6-8-10-15)31-20(28)22(3,4)5/h6-10,13-14,17,19H,11-12H2,1-5H3,(H,25,29)/t17-,19?/m0/s1 |
| InChIKey | QQIBFRQTTLIECS-KKFHFHRHSA-N |
| SMILES | CC(C)OC(=O)C(CCC(=O)C=[N+]=[N-])NC(=O)OC(C1=CC=CC=C1)OC(=O)C(C)(C)C |
| Reference | [1]. Lemberg KM, et al. The novel glutamine antagonist prodrug JHU395 has antitumor activity in malignant peripheralnerve sheath tumor. Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0319.2019. |
